Literature DB >> 28121069

A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors.

Irene Tadeo1, Ana P Berbegall1, Samuel Navarro1, Victoria Castel2, Rosa Noguera1.   

Abstract

PURPOSE AND
OBJECTIVE: Improved prognosis for patients with peripheral neuroblastic tumors (PNB) depends on enhanced pretreatment risk stratification combined with research into new therapeutic targets. This study investigated the potential contribution of extracellular matrix (ECM) elements toward this endeavor.
METHODS: We characterized certain elements such as reticulin fibers, collagen type I fibers, and elastic fibers by digital pathology in almost 400 untreated PNB.
RESULTS: A reticular and poorly porous ECM was identified in neuroblastomas (NBs) from patients with clinical and biological features associated with poor prognosis compared with a loose and permeable matrix found in NBs of the favorable cohort.
CONCLUSIONS: Aggressiveness patterns of ECM can be accurately determined by morphometric tools and could become candidate elements for novel therapies.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  collagen fibers; elastic fibers; extracellular matrix; microscopic digital pathology; neuroblastoma; reticulin fibers

Mesh:

Year:  2017        PMID: 28121069     DOI: 10.1002/pbc.26449

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome.

Authors:  Yiyang Chen; Lina Marie Hoffmeister; Yasmin Zaun; Lucas Arnold; Kurt Werner Schmid; Bernd Giebel; Ludger Klein-Hitpass; Helmut Hanenberg; Anthony Squire; H Christian Reinhardt; Ulrich Dührsen; Stefanie Bertram; Maher Hanoun
Journal:  Blood Adv       Date:  2020-10-27

Review 2.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

Review 3.  Integrating the Tumor Microenvironment into Cancer Therapy.

Authors:  Sabina Sanegre; Federico Lucantoni; Rebeca Burgos-Panadero; Luis de La Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

4.  The topology of vitronectin: A complementary feature for neuroblastoma risk classification based on computer-aided detection.

Authors:  Pablo Vicente-Munuera; Rebeca Burgos-Panadero; Inmaculada Noguera; Samuel Navarro; Rosa Noguera; Luis M Escudero
Journal:  Int J Cancer       Date:  2019-07-08       Impact factor: 7.396

Review 5.  The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Authors:  Irena Horwacik
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

6.  Lymph microvascularization as a prognostic indicator in neuroblastoma.

Authors:  Irene Tadeo; Esther Gamero-Sandemetrio; Ana P Berbegall; Marta Gironella; Félix Ritort; Adela Cañete; Gloria Bueno; Samuel Navarro; Rosa Noguera
Journal:  Oncotarget       Date:  2018-05-25

7.  Digital Image Analysis Applied to Tumor Cell Proliferation, Aggressiveness, and Migration-Related Protein Synthesis in Neuroblastoma 3D Models.

Authors:  Ezequiel Monferrer; Sabina Sanegre; Susana Martín-Vañó; Andrea García-Lizarribar; Rebeca Burgos-Panadero; Amparo López-Carrasco; Samuel Navarro; Josep Samitier; Rosa Noguera
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

8.  Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line.

Authors:  Amparo López-Carrasco; Susana Martín-Vañó; Rebeca Burgos-Panadero; Ezequiel Monferrer; Ana P Berbegall; Beatriz Fernández-Blanco; Samuel Navarro; Rosa Noguera
Journal:  J Exp Clin Cancer Res       Date:  2020-10-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.